ERRFI1 and neoplasm: Our demonstration that miR‐205‐driven ERRFI1 loss is sufficient to confer vicarious oncogenic properties to EGFR signaling is congruent with (i) biochemical studies that assign to ERRFI1 a role as pan‐ERBB inhibitor; (ii) genetic analyses in the mouse that have nominated Errfi1 as a tumor suppressor; (iii) biological experiments in glioblastoma, NSCLC, and pancreatic carcinoma cells that point to ERRFI1 loss as key mechanism in sustaining oncogenic addiction to EGFR signaling (reviewed in Anastasi et al, 2016).